Correction: CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Juan Lantero-Rodriguez, Laia Montoliu-Gaya, Andrea L. Benedet, Agathe Vrillon, Julien Dumurgier, Emmanuel Cognat, Wagner S. Brum, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Joseph Therriault, Bruno Becker, Gunnar Brinkmalm, Anniina Snellman, Hanna Huber, Hlin Kvartsberg
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAlzheimer's disease research and treatments
Correction: Acta Neuropathologica (2024) 147:12 10.1007/s00401-023-02659-w
In this article, the following sentence with the term serine 205 was incorrectly published in the section Materials and methods under the subsection Simoa CSF p‑tau202 and p‑tau205 measurements:
Similarly, in the CSF p-tau205 immunoassay, a rabbit polyclonal antibody selective against phosphorylated tau at serine 205 (immunogen: synthesized human tau peptide around the phosphorylation site of serine205, ThermoFisher Scientific) was used as capture antibody with biotinylated Tau12 used for detection.
The correct term should be threonine 205, and the correct sentence should be as given below:
Similarly, in the CSF p-tau205 immunoassay, a rabbit polyclonal antibody selective against phosphorylated tau at threonine 205 (immunogen: synthesized human tau peptide around the phosphorylation site of threonine205, ThermoFisher Scientific) was used as capture antibody with biotinylated Tau12 used for detection.
Now, the original has been corrected.